Regulators will review data on satri-cel's ability to treat advanced Claudin18.2-positive tumors in an expedited timeline.

The firm will use the proceeds from the private placement to advance its clinical-stage cardiomyopathy gene therapy programs.

The firm has inked a debt financing agreement with Blue Owl Capital and will use the funds to launch ITM-11in the US market following approval.

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Autolus Therapeutics' autologous CD19-directed CAR T-cell therapy Aucatzyl ...

In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed ...

The analysis by Ontada tracked testing rates within the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 ...

Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

The treatment has been used in a trial to treat children with GM1 gangliosidosis, but if the FDA allows, this would be the ...

Investigators presented interim data from a Phase III trial of Lenmeldy in patients with the late juvenile form of disease at ...

The firms launched the global Phase II bladder cancer trial for autogene cevumeran after seeing early success in pancreatic ...

Avenzo gets FDA permission to proceed with Phase I/II trials of an EGFR/HER3 bispecific antibody and a CDK4 inhibitor in select solid tumors.